This ECM-related mechanism, if it takes place in vivo, may explain the resistance of gastric cancer to CAR-T cell therapy and implies a possibility to improve the therapeutic effect by neutralizing KynA or by inhibiting the AHR pathway. The gene discussed is AHR; the disease is gastric cancer.